Results 91 to 100 of about 141,477 (341)

Impact of Diabetes on Long‐Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Diabetes mellitus (DM) is a well‐known risk factor for cardiovascular diseases, including coronary artery diseases (CAD). Complex percutaneous coronary intervention (PCI) such as PCI for bifurcation lesions often yields poor outcomes, especially in DM patients.
Subin Lim, Soon Jun Hong, Ju Hyeon Kim, Jung‐Joon Cha, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Do‐Sun Lim, Chang‐Wook Nam, the COBIS III investigators, Hyo‐Soo Kim, Woo Jung Chun, Seung‐Ho Hur, Seung Hwan Han, Seung‐Woon Rha, In‐Ho Chae, Jin‐Ok Jeong, Jung Ho Heo, Junghan Yoon, Ki Hong Choi, Young Bin Song, Hyeon‐Cheol Gwon, Jong‐Seon Park, Myeong‐Ki Hong, Joon‐Hyung Doh, Kwang Soo Cha, Doo‐Il Kim, Sang Yeub Lee, Kiyuk Chang, So‐Yeon Choi, Myung Ho Jeong, Bon‐Kwon Koo   +31 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis.

PLoS ONE, 2011
The P2Y12 receptor plays a crucial role in the regulation of platelet activation by several agonists, which is irreversibly antagonized by the active metabolite of clopidogrel, a widely used anti-thrombotic drug.
Analia E Garcia, Sripal R Mada, Mario C Rico, Raul A Dela Cadena, Satya P Kunapuli   +4 more
doaj   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source

The Method of Forecasting of the Indicators for Drug Reimbursement to Patients with Cardiovascular Diseases in Ukraine [PDF]

, 2019
The aim of the study is to develop a method for forecasting the indicators for drug reimbursement to patients with cardiovascular diseases (CVD) in Ukraine within the framework of the government program “Available medicines”.Materials and methods ...
Kurylenko, Y. (Yuliia), Nazarkina, V. (Viktoriya), Nemchenko, A. (Alla)   +2 more
core   +3 more sources

Clopidogrel–Drug Interactions

Journal of the American College of Cardiology, 2011
Multidrug therapy increases the risk for drug-drug interactions. Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y₁₂ adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggregation processes. Atorvastatin, omeprazole, and several other
Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan ( host institution ), Bates, Eric R., Lau, Wei C., Angiolillo, Dominick J.   +3 more
openaire   +4 more sources

Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long‐term outcomes in patients with cardiovascular disease are not well understood. Objective: We studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients ...
Sumon Roy, Annette Min, Edward O. McFalls, Robert A. Perera, Fadi N. Salloum, Ion S. Jovin   +5 more
wiley   +1 more source

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]

, 2016
A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE, PIGNATELLI, Pasquale, Soliman, Elsayed Z, VIOLI, Francesco   +3 more
core   +1 more source

Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium

Clinical pharmacology and therapy, 2020
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in this response, but account for only a small proportion of variability in
S. Verma, T. Bergmeijer, L. Gong, J. Reny, J. Lewis, B. Mitchell, D. Alexopoulos, D. Aradi, R. Altman, K. Bliden, Y. Bradford, G. Campo, Kiyuk Chang, J. Cleator, J. Dery, N. Dridi, I. Férnandez-Cadenas, P. Fontana, M. Gawaz, T. Geisler, G. Gensini, B. Giusti, P. Gurbel, W. Hochholzer, L. Holmvang, Eun-Young Kim, Ho-Sook Kim, R. Marcucci, J. Montaner, J. Backman, R. Pakyz, D. Roden, E. Schaeffeler, M. Schwab, Jae-Gook Shin, J. Siller-Matula, J. T. ten Berg, D. Trenk, M. Valgimigli, John M. Wallace, M. Wen, M. Kubo, M. Lee, R. Whaley, S. Winter, T. Klein, A. Shuldiner, M. Ritchie   +47 more
semanticscholar   +1 more source